ALDX · Insider Trading
Aldeyra Therapeutics, Inc.
Every open-market purchase and sale reported by ALDX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-11 | Nancy Miller-Rich | Director | A | +73,318 deriv. | — |
| 2026-06-11 | Neal Walker | Director | A | +73,318 deriv. | — |
| 2026-06-11 | Ben Bronstein | Director | A | +80,286 deriv. | — |
| 2026-06-11 | Richard Douglas | Director | A | +92,232 deriv. | — |
| 2026-06-11 | Gary M. Phillips | Director | A | +81,613 deriv. | — |
| 2026-06-11 | William D Clark | Director | A | +72,323 deriv. | — |
| 2026-06-11 | Darlene M Deptula-Hicks | Director | A | +94,313 deriv. | — |
| 2026-06-05 | Todd C Brady | President and CEO | Buy | +250,000 | +$418.45K |
| 2026-03-20 | Richard Douglas | Director | Buy | +70,000 | +$98.00K |
| 2026-03-19 | Michael Alfieri | Principal Financial Officer | Buy | +5,000 | +$7.10K |
| 2025-08-15 | Michael Alfieri | Principal Financial Officer | Buy | +2,500 | +$13.25K |
| 2025-08-13 | Stephen Machatha | Chief Development Officer | Sell | −22,073 | −$113.71K |
| 2025-06-12 | Neal Walker | Director | A | +65,141 deriv. | — |
| 2025-06-12 | Richard Douglas | Director | A | +78,893 deriv. | — |
| 2025-06-12 | Nancy Miller-Rich | Director | A | +65,141 deriv. | — |
| 2025-06-12 | Gary M. Phillips | Director | A | +71,172 deriv. | — |
| 2025-06-12 | Ben Bronstein | Director | A | +70,207 deriv. | — |
| 2025-06-12 | Martin Joseph Joyce | Director | A | +71,655 deriv. | — |
| 2025-04-18 | William D Clark | Director | A | +76,760 deriv. | — |
| 2025-04-07 | Joseph Edelman | 10%+ Owner | Sell | −10,200,000 | −$14.48M |
| 2025-03-06 | Stephen Machatha | Chief Development Officer | A | +202,427 deriv. | — |
| 2025-03-06 | Todd C Brady | President and CEO | A | +809,710 deriv. | — |
| 2024-10-21 | Nancy Miller-Rich | Director | Buy | +922 | +$10.45K |
| 2024-08-14 | Stephen Machatha | Chief Development Officer | Sell | −16,041 | −$75.97K |
| 2024-08-14 | Bruce Greenberg | See Remarks | Sell | −10,834 | −$51.31K |
| 2024-06-06 | Martin Joseph Joyce | Director | A | +46,706 deriv. | — |
| 2024-06-06 | Ben Bronstein | Director | A | +45,664 deriv. | — |
| 2024-06-06 | Neal Walker | Director | A | +42,018 deriv. | — |
| 2024-06-06 | Gary M. Phillips | Director | A | +46,359 deriv. | — |
| 2024-06-06 | Richard Douglas | Director | A | +51,915 deriv. | — |
| 2024-06-06 | Nancy Miller-Rich | Director | A | +42,018 deriv. | — |
| 2024-04-17 | Bruce Greenberg | See Remarks | Sell | −13,201 | −$44.97K |
| 2024-04-17 | Stephen Machatha | Chief Development Officer | Sell | −11,537 | −$36.50K |
| 2024-04-08 | Joseph Edelman | 10%+ Owner | Buy | +533,979 | +$2.50M |
| 2024-04-03 | Joseph Edelman | 10%+ Owner | Buy | +1,512,816 | +$5.80M |
| 2024-03-12 | Bruce Greenberg | See Remarks | Sell | −13,201 | −$44.97K |
| 2024-03-12 | Stephen Machatha | Chief Development Officer | Sell | −29,768 | −$98.61K |
| 2024-03-12 | Todd C Brady | President and CEO | Sell | −183,238 | −$580.76K |
| 2023-10-18 | Joseph Edelman | 10%+ Owner | Sell | −8,269,497 | −$13.36M |
| 2023-09-11 | Gary M. Phillips | Director | M | +5,437 | +$3.00K |
| 2023-09-11 | Todd C Brady | President and CEO | MIXED | +199,251 | −$382.16K |
| 2023-08-24 | Neal Walker | Director | M | +9,604 | +$5.30K |
| 2023-07-05 | Nancy Miller-Rich | Director | A | +22,137 deriv. | — |
| 2023-07-05 | Gary M. Phillips | Director | A | +24,423 deriv. | — |
| 2023-07-05 | Richard Douglas | Director | A | +27,350 deriv. | — |
| 2023-07-05 | Martin Joseph Joyce | Director | A | +24,606 deriv. | — |
| 2023-07-05 | Ben Bronstein | Director | A | +24,058 deriv. | — |
| 2023-07-05 | Neal Walker | Director | A | +22,137 deriv. | — |
| 2023-06-29 | Ben Bronstein | Director | M | +9,604 | +$5.30K |
| 2023-03-02 | Bruce Greenberg | See Remarks | A | −110,028 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Joseph Edelman | 10%+ Owner | 5,875,851 | $4.03M |
| Todd C Brady | President and CEO | 1,721,298 | $1.18M |
| Stephen Machatha | Chief Development Officer | 222,010 | $152.10K |
| Richard Douglas | Director | 195,000 | $133.59K |
| Ben Bronstein | Director | 28,248 | $19.35K |
| Martin Joseph Joyce | Director | 23,967 | $16.42K |
| Neal Walker | Director | 15,854 | $10.86K |
| Gary M. Phillips | Director | 14,812 | $10.15K |
| Michael Alfieri | Principal Financial Officer | 7,500 | $5.14K |
| Nancy Miller-Rich | Director | 413 | $283 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ALDX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.